Medical Devices APAC

APAC Rare Disease Diagnostics Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

APAC Rare Disease Diagnostics Market Industry Trends and Forecast to 2034: Segmented by (Technology, Patient, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $445.3 Mn Placeholder estimate
Estimate 2025 $500.5 Mn 22.6% of the global market
Projected 2034 $1.43 Bn 186.3% Adds $932.8 Mn over 9 forecast years
CAGR 2025–2034 12.4% Faster than 66% of 173 Medical Devices markets here
Key players 5 Companies profiled
  • APAC is 22.57% of the global market.
  • Among regions, the largest is North America at $1.24 Bn.
  • Fastest growing: APAC (this report) at 12.4% a year.
  • APAC ranks 2nd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$932.8 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Rare Disease Diagnostics Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $445.3 Mn — —
2025 (base) $500.5 Mn +$55.2 Mn —
2026 (forecast) $562.6 Mn +$62.1 Mn +12.4%
2027 (forecast) $632.4 Mn +$69.8 Mn +26.3%
2028 (forecast) $710.8 Mn +$78.4 Mn +42%
2029 (forecast) $798.9 Mn +$88.1 Mn +59.6%
2030 (forecast) $898.0 Mn +$99.1 Mn +79.4%
2031 (forecast) $1.01 Bn +$111.4 Mn +101.6%
2032 (forecast) $1.13 Bn +$125.2 Mn +126.7%
2033 (forecast) $1.28 Bn +$140.7 Mn +154.8%
2034 (forecast) $1.43 Bn +$158.1 Mn +186.3%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $2.22 Bn
  2. North America $1.24 Bn
  3. US $899.1 Mn
  4. APAC (this report) $500.5 Mn
  5. Europe $390.3 Mn
  6. Canada $185.0 Mn
  7. China $180.5 Mn
  8. Japan $125.5 Mn
  9. Middle East $91.1 Mn
  10. Latin America $89.6 Mn
  11. Germany $78.6 Mn
  12. France $65.8 Mn
  13. Italy $57.5 Mn
  14. UK $50.8 Mn
  15. Ecuador $49.1 Mn
  16. Brazil $49.0 Mn
  17. Spain $44.7 Mn
  18. India $47.1 Mn
  19. Saudi Arabia $37.7 Mn
  20. Africa $35.2 Mn
  21. Mexico $31.0 Mn
  22. New Zealand $23.1 Mn
  23. Australia $23.5 Mn
  24. Russia $20.6 Mn
  25. South Africa $16.3 Mn
  26. UAE $11.3 Mn
  27. Egypt $6.9 Mn
  28. Philippines $5.1 Mn
  29. Hong Kong $3.9 Mn
  30. Malaysia $3.3 Mn
  31. Singapore $2.6 Mn
  32. Thailand $2.5 Mn
  33. Kenya $1.4 Mn

Report snapshot

APAC Rare Disease Diagnostics Market Analysis at a glance
Market size, 2025$500.5 Mn placeholder estimate
Forecast, 2034$1.43 Bn placeholder estimate
Growth (CAGR), 2025–203412.4% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTechnology, patient and end user (see all)
Key playersGeneDx, CENTOGENE, Invitae, FDNA, Illumina, Inc. (see all)
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The APAC Rare Disease Diagnostics Market Analysis Executive Summary

Rare disease diagnostics help find the cause of rare conditions faster, using genetic tests, biomarkers and AI tools that read symptoms.

Key segments of the rare Disease Diagnostics market include technology (Genetic Sequencing, Biochemical Tests and AI Symptom Matching) and patient (Pediatric and Adult).

Bar chart: Asia Pacific Rare Disease Diagnostics market size, 2024–2034, placeholder estimates. $445.3 Mn in 2024, $500.5 Mn in 2025 and $1.43 Bn in 2034, 12.4% CAGR.
Asia Pacific Rare Disease Diagnostics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

APAC Rare Disease Diagnostics Market Dynamics

Market Growth Drivers

Better genetic diagnosis, orphan drug incentives, patient advocacy and new gene and enzyme therapies are driving the rare Disease Diagnostics market. More countries now have national rare disease plans.

Opportunity

Newborn genome screening, gene therapies and access programmes in emerging markets give the rare Disease Diagnostics market strong growth.

Market Restraints

Very small patient numbers, long diagnosis delays, high treatment prices and limited specialist centres hold back the rare Disease Diagnostics market.

Competitive Landscape for Rare Disease Diagnostics Market in APAC

The rare Disease Diagnostics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Rare Disease Diagnostics Market in APAC

Rare Disease Diagnostics in APAC: rules and payment

In some of the countries we cover here, medical devices are regulated by TGA (Australia)⁠[1], NMPA (China)⁠[2], MDACS (Hong Kong)⁠[3], CDSCO (India)⁠[4], PMDA (Japan)⁠[5], MDA (Malaysia)⁠[6], Medsafe (WAND) (New Zealand)⁠[7], FDA Philippines (Philippines)⁠[8], HSA (Singapore)⁠[9] and Thai FDA (Thailand)⁠[10]. How care is paid for in some of these countries: Medicare and the PBS (Australia)⁠[11], basic medical insurance (China)⁠[12], the Hospital Authority (Hong Kong)⁠[13], Ayushman Bharat PM-JAY (India)⁠[14], public health insurance (Japan)⁠[15], subsidised public care (Malaysia)⁠[16], Pharmac (New Zealand)⁠[17], PhilHealth (Philippines)⁠[18], MediShield Life (Singapore)⁠[19] and the Universal Coverage Scheme (Thailand)⁠[20].

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] National Medical Products Administration. Checked 14 Nov 2026.

[3] Medical Device Division, Department of Health. Checked 14 Nov 2026.

[4] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[5] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[6] Medical Device Authority. Checked 14 Nov 2026.

[7] Medsafe. Checked 14 Nov 2026.

[8] Food and Drug Administration Philippines. Checked 14 Nov 2026.

[9] Health Sciences Authority. Checked 14 Nov 2026.

[10] Thai Food and Drug Administration. Checked 14 Nov 2026.

[11] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[12] National Healthcare Security Administration. Checked 14 Nov 2026.

[13] Hospital Authority. Checked 14 Nov 2026.

[14] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[15] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[16] Ministry of Health Malaysia. Checked 14 Nov 2026.

[17] Pharmac. Checked 14 Nov 2026.

[18] PhilHealth. Checked 14 Nov 2026.

[19] CPF Board, MediShield Life. Checked 14 Nov 2026.

[20] National Health Security Office. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how rare Disease Diagnostics products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in APAC.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Rare Disease Diagnostics right now, from free public sources.

Latest research 69 papers since 2021 (worldwide)

  1. Long-read RNA sequencing improves isoform and splicing outlier detection in whole blood from rare disease trios. medRxiv : the preprint server for health sciences, 2026
  2. Intron Retention Caused by a Novel Homozygous LNPK Splice-Site Variant Leading to Severe Neurodevelopmental Disorder and Epilepsy. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, 2026
  3. Population-Specific Carrier Frequencies in an Underrepresented Genetically Heterogeneous Population: Implications for Expanded Carrier Screening. Genes, 2026
  4. The transformative impact of ultra-rapid nanopore sequencing in precision medicine. Frontiers in immunology, 2026
  5. Financing and health system capacity for precision medicine in Asia: a six country landscape analysis. Health affairs scholar, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Rare Disease Diagnostics in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Rare Disease Diagnostics market in Asia Pacific?
Placeholder estimate: about $500.5 Mn in 2025, rising to about $1.43 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Rare Disease Diagnostics market in Asia Pacific growing?
Placeholder estimate: about 12.4% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Rare Disease Diagnostics market report cover?
The report splits the market by technology (Genetic Sequencing, Biochemical Tests, AI Symptom Matching), patient (Pediatric, Adult) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Rare Disease Diagnostics market?
Key players include GeneDx, CENTOGENE, Invitae, FDNA and Illumina, Inc..
What is driving the Rare Disease Diagnostics market?
Better genetic diagnosis, orphan drug incentives, patient advocacy and new gene and enzyme therapies are driving the rare Disease Diagnostics market. More countries now have national rare disease plans.
How much research is published on Rare Disease Diagnostics?
PubMed lists 69 papers on Rare Disease Diagnostics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Rare Disease Diagnostics in APAC? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard

From our blog

Dermatology Diagnostics: AI and Skin HealthSkin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions… Molecular Point-of-Care Tests: Lab Accuracy, Clinic SpeedTB killed 1.23 million people in 2024. WHO now recommends rapid molecular tests first, bringing lab-grade… Healthcare In-Vitro Diagnostics: What Comes After COVIDCOVID-19 testing created a huge, short-lived spike. Long-term demand for in-vitro diagnostics now comes from…
Back to Catalogue
Keep exploring

Related Medical Devices reports in APAC

See all
Same topic, other categories

Related on rare diseases and genomics

See the topic